NASDAQ:GERN - Nasdaq - US3741631036 - Common Stock - Currency: USD
2.57
-0.06 (-2.28%)
The current stock price of GERN is 2.57 USD. In the past month the price decreased by -14.9%. In the past year, price increased by 31.12%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 141 full-time employees. The firm is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. The company is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. The company is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
GERON CORP
919 East Hillsdale Boulevard, Suite 250
Foster City CALIFORNIA 94404 US
CEO: John A. Scarlett
Employees: 141
Company Website: https://www.geron.com/
Investor Relations: https://ir.geron.com/
Phone: 16504737700
The current stock price of GERN is 2.57 USD. The price decreased by -2.28% in the last trading session.
The exchange symbol of GERON CORP is GERN and it is listed on the Nasdaq exchange.
GERN stock is listed on the Nasdaq exchange.
15 analysts have analysed GERN and the average price target is 7.88 USD. This implies a price increase of 206.48% is expected in the next year compared to the current price of 2.57. Check the GERON CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GERON CORP (GERN) has a market capitalization of 1.55B USD. This makes GERN a Small Cap stock.
GERON CORP (GERN) currently has 141 employees.
GERON CORP (GERN) has a support level at 2.55 and a resistance level at 2.78. Check the full technical report for a detailed analysis of GERN support and resistance levels.
The Revenue of GERON CORP (GERN) is expected to grow by 26300.3% in the next year. Check the estimates tab for more information on the GERN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GERN does not pay a dividend.
GERON CORP (GERN) will report earnings on 2025-02-26, before the market open.
GERON CORP (GERN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.32).
The outstanding short interest for GERON CORP (GERN) is 12.35% of its float. Check the ownership tab for more information on the GERN short interest.
ChartMill assigns a fundamental rating of 2 / 10 to GERN. GERN may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months GERN reported a non-GAAP Earnings per Share(EPS) of -0.32. The EPS increased by 5.88% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -45.22% | ||
ROE | -68.83% | ||
Debt/Equity | 0.04 |
ChartMill assigns a Buy % Consensus number of 85% to GERN. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 14.69% and a revenue growth 26300.3% for GERN